Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07659782 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Study acronym: TARGET-D 202
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 17 to 19
  2. Study sites: 16 to 17
  3. Study sites: 15 to 16
  4. Study sites: 13 to 15
  5. Study sites: 12 to 13 Eligibility criteria expanded, about 22 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 22 words
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 11 to 12v9
  2. Study sites: 10 to 11v8
  1. Trial sites expanded: 7 → 10 locationsv7
  2. Study sites: 6 to 7v6
  3. Study sites: 4 to 6v5
  4. Study sites: 3 to 4 Start date changed from estimate of Jul 2026 to Jul 22, 2026v4 Show 1 more changeShow less
    • Start date changed from estimate of Jul 2026 to Jul 22, 2026
  5. Recruitment opened Start date: Jun 2026 to Jul 2026 · Site details revised at 3 of 3 sitesv3 Show 2 more changesShow less
    • Start date: Jun 2026 to Jul 2026
    • Site details revised at 3 of 3 sites
  6. Trial sites expanded: 0 → 3 locationsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
Trial Details
NCT Number NCT07659782
Lead Sponsor Verastem, Inc.
Conditions Non-Small Cell Lung Cancer
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov